Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
Kang Chen, Wei Wei, Lei Liu, Zhu‐Jian Deng, Le Li, Xiumei Liang, Pingping Guo, Lu‐Nan Qi, Zhiming Zhang, Wen‐Feng Gong, Shan Huang, Weiping Yuan, Liang Ma, Bang‐De Xiang, Le‐Qun Li, Jian‐Hong Zhong
Topics & Concepts
LenvatinibMedicineInternal medicineHazard ratioHepatocellular carcinomaAdverse effectOncologyNivolumabSorafenibCancerImmunotherapyConfidence intervalHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesCancer Mechanisms and Therapy